compounding tirzepatide fda ban on compounded tirzepatide: Switch to name brand medications May 18, 2026: FDA warns

Store in sealed, shaded containers at room temperature (between 1~30)

Dimensions: 7800 x 3671 px | 66 x 31.1 cm | 26 x 12.2 inches | 300dpi Date taken: 26 January 2026 Photographer: RUSLANAS BARANAUSKAS/SCIENCE PHOTO LIBRARY

A clinical trial involving over 600 adults with obesity showed that those who took the injectable form for 68 weeks lost an average of 15.3% of their body weight, compared to 12.4% with oral Semaglutide GLP-1

While supplies have been increasing, both drugs remain on the FDAs drug shortage database, suggesting that many diabetes patients may be struggling to obtain them, and may have serious health complications as a result